The trajectory of the erectile dysfunction drug presents a intricate picture for investors. While the initial launch generated substantial profits, the lapse of its patent opened the floodgates to generic alternatives, dramatically reducing sales. This creates a particular challenge for pharmaceutical companies banking on comparable blockbuster off

The story of Viagra, and its parent company copyright, presents a intriguing case study for investors. Originally a blockbuster drug, yielding billions in income, its patent expiration created a flood of lower-priced alternatives , significantly diminishing its position . While some businesses may attempt to capitalize on related treatments , the c